Felodipine-influenced gingival enlargement in an uncontrolled type 2 diabetic patient

Journal of Periodontology

Volumn 76, Issue 7, 2005, Pages 1217-1222

  Fay, Ann Adams ^a   Satheesh, Keerthana ^a   Gapski, Ricardo ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Calcium channel blockers; Diabetes, non insulin dependent; Felodipine adverse effects; Gingival hyperplasia therapy; Gingival hyperplasia etiology

Indexed keywords

AMOXICILLIN; ATENOLOL; CHLORHEXIDINE; COLLAGEN; FELODIPINE; METFORMIN; MEVINOLIN; MULTIVITAMIN; OLMESARTAN;

ADULT; ARTICLE; CASE REPORT; CONSERVATIVE TREATMENT; CONSULTATION; DIABETES CONTROL; DISEASE SEVERITY; DRUG WITHDRAWAL; GINGIVA HYPERTROPHY; GINGIVAL BIOPSY; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATORY INFILTRATE; LYMPHOCYTE; MAINTENANCE THERAPY; MALE; MEDICAL DOCUMENTATION; MOUTH HYGIENE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVENTIVE DENTISTRY; RECURRENT DISEASE; SURGICAL TECHNIQUE; TOOTH EXTRACTION;

ALVEOLAR BONE LOSS; ANTI-BACTERIAL AGENTS; ANTICHOLESTEREMIC AGENTS; CALCIUM CHANNEL BLOCKERS; DENTAL CARE FOR CHRONICALLY ILL; DENTAL SCALING; DIABETES MELLITUS, TYPE 2; FELODIPINE; GINGIVAL HYPERPLASIA; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED;

EID: 23044460278     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2005.76.7.1217     Document Type: Article

References (56)

1. Hassell TM, Gilbert GH. Phenytoin sensitivity of fibroblasts as the basis for susceptibility to gingival enlargement. Am J Pathol 1983;112:218-223.
2. Casetta I, Granieri E, Desidera M, et al. Phenytoin-induced gingival overgrowth: A community-based cross-sectional study in Ferrara, Italy. Neuroepidemiology 1997;16:296-303.
3. Brunsvold M, Tomasovic J, Ruemping D. The measured effect of phenytoin withdrawal on gingival hyperplasia in children. ASDC J Dent Child 1985;52:417-421.
4. Rateitschak-Pluss EM, Hefti A, Lortscher R, Thiel G. Initial observation that cyclosporin-A induces gingival enlargement in man. J Clin Periodontol 1983;10:237-246.
5. Pisanty S, Rahamim E, Ben-Ezra D, Shoshan S. Prolonged systemic administration of cyclosporin A affects gingival epithelium. J Periodontol 1990;61:138-141.
6. Daly CG. Resolution of cyclosporin A (CsA)-induced gingival enlargement following reduction in CsA dosage. J Clin Periodontol 1992;19:143-145.
7. Barak S, Engelberg IS, Hiss J. Gingival hyperplasia caused by nifedipine. Histopathologic findings. J Periodontol 1987;58:639-642.
8. Romanos GE, Schroter-Kermani C, Hinz N, Herrmann D, Strub JR, Bernimoulin JP. Extracellular matrix analysis of nifedipine-induced gingival overgrowth: Immunohistochemical distribution of different collagen types as well as the glycoprotein fibronectin. J Periodontal Res 1993; 28:10-16.
9. Miranda J, Brunet L, Roset P, Berini L, Farre M, Mendieta C. Prevalence and risk of gingival enlargement in patients treated with nifedipine. J Periodontol 2001; 72:605-611.
10. Pernu HE, Oikarinen K, Hietanen J, Knuuttila M. Verapamil-induced gingival overgrowth: A clinical, histologic, and biochemic approach. J Oral Pathol Med 1989;18: 422-425.
11. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992;63:453-456.
12. Mehta AV, Chidambaram B, O'Riordan AC. Verapamil-induced gingival hyperplasia in children. Am Heart J 1992;124:535-536.
13. Giustiniani S, Robustelli della Cuna F, Marieni M. Hyperplastic gingivitis during diltiazem therapy. Int J Cardiol 1987;15:247-249.
14. Fattore L, Stablein M, Bredfeldt G, Semla T, Moran M, Doherty-Greenberg JM. Gingival hyperplasia: A side effect of nifedipine and diltiazem. Spec Care Dentist 1991;11:107-109.
15. Hallmon WW, Rossmann JA. The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontol 2000 1999;21:176-196.
16. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996;23:165-175.
17. Butler RT, Kalkwarf KL, Kaldahl WB. Drug-induced gingival hyperplasia: Phenytoin, cyclosporine, and nifedipine. J Am Dent Assoc 1987;114:56-60.
18. Bhathal PS, Gall JA. Deletion of hyperplastic biliary epithelial cells by apoptosis following removal of the proliferative stimulus. Liver 1985;5:311-325.
19. Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: An overview. Cancer Metastasis Rev 1992;11:95-103.
20. Fesus L, Davies PJ, Piacentini M. Apoptosis: Molecular mechanisms in programmed cell death. Eur J Cell Biol 1991;56:170-177.
21. Hassell TM, Hefti AF. Drug-induced gingival overgrowth: Old problem, new problem. Crit Rev Oral Biol Med 1991;2:103-137.
22. Godfraind T. Mechanisms of action of calcium entry blockers. Fed Proc 1981;40:2866-2871.
23. Soward AL, Vanhaleweyk GL, Serruys PW. The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review. Drugs 1986;32:66-101.
24. Seymour RA. Calcium channel blockers and gingival overgrowth. Br Dent J 1991;170:376-379.
25. Lederman D, Lumerman H, Reuben S, Freedman PD. Gingival hyperplasia associated with nifedipine therapy. Report of a case. Oral Surg Oral Med Oral Pathol 1984;57:620-622.
26. Ramon Y, Behar S, Kishon Y, Engelberg IS. Gingival hyperplasia caused by nifedipine - a preliminary report. Int J Cardiol 1984;5:195-206.
27. Slavin J, Taylor J. Cyclosporin, nifedipine, and gingival hyperplasia. Lancet 1987;2:739.
28. Nishikawa S, Tada H, Hamasaki A, et al. Nifedipine-induced gingival hyperplasia: A clinical and in vitro study. J Periodontol 1991;62:30-35.
29. Lucas RM, Howell LP, Wall BA. Nifedipine-induced gingival hyperplasia. A histochemical and ultrastructural study. J Periodontol 1985;56:211-215.
30. Routray SN, Mishra TK, Pattnaik UK, Satapathy C, Mishra CK, Behera M. Amlodipine-induced gingival hyperplasia. J Assoc Physicians India 2003;51:818-819.
31. Thomason JM, Seymour RA, Soames JV. Severe mucosal hyperplasia of the edentulous maxilla associated with immunosuppressant therapy: A clinical report. J Prosthet Dent 1994;72:1-3.
32. Brown RS, Sein P, Corio R, Bottomley WK. Nitrendipine-induced gingival hyperplasia. First case report. Oral Surg Oral Med Oral Pathol 1990;70:593-596.
33. Ikawa K, Ikawa M, Shimauchi H, Iwakura M, Sakamoto S. Treatment of gingival overgrowth induced by manidipine administration. A case report. J Periodontol 2002;73:115-122.
34. Lombardi T, Fiore-Donno G, Belser U, Di Felice R. Felodipine-induced gingival hyperplasia: A clinical and histologic study. J Oral Pathol Med 1991;20:89-92.
35. Safholm C, Havu N. General toxicity of the new calcium antagonist felodipine in dogs. Arzneimittelforschung 1993;43:729-733.
36. Young PC, Turiansky GW, Sau P, Liebman MD, Benson PM. Felodipine-induced gingival hyperplasia. Cutis 1998;62:41-43.
37. Shouda J, Nakamoto H, Sugahara S, Okada H, Suzuki H. Incidence of gingival hyperplasia caused by calcium antagonists in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 1999;15:153-155.
38. Jassim al Khaja KA, Sequeira RP, Wahab AW, Mathur VS. Antihypertensive drug prescription trends at the primary health care centres in Bahrain. Pharmacoepidemiol Drug Saf 2001;10:219-227.
39. Lokken P, Skomedal T. Gingival hyperplasia induced by calcium channel blockers. Rare or frequent in Norway? (in Norwegian). Tidsskr Nor Laegeforen 1992;112:1978-1980.
40. Glavind L, Lund B, Löe H. The relationship between periodontal state and diabetes duration, insulin dosage and retinal changes. J Periodontol 1968;39:341-347.
41. Cohen DW, Friedman LA, Shapiro J, Kyle GC, Franklin S. Diabetes mellitus and periodontal disease: Two-year longitudinal observations. I. J Periodontol 1970;41:709-712.
42. Cianciola LJ, Park BH, Bruck E, Mosovich L, Genco RJ. Prevalence of periodontal disease in insulin-dependent diabetes mellitus (juvenile diabetes). J Am Dent Assoc 1982;104:653-660.
43. Noack B, Jachmann I, Roscher S, et al. Metabolic diseases and their possible link to risk indicators of periodontitis. J Periodontol 2000;71:898-903.
44. McMullen JA, Van Dyke TE, Horoszewicz HU, Genco RJ. Neutrophil chemotaxis in individuals with advanced periodontal disease and a genetic predisposition to diabetes mellitus. J Periodontol 1981;52:167-173.
45. Van Dis ML, Allen CM, Neville BW. Erythematous gingival enlargement in diabetic patients: A report of four cases. J Oral Maxillofac Surg 1988;46:794-798.
46. Bartolucci EG, Parkes RB. Accelerated periodontal breakdown in uncontrolled diabetes. Pathogenesis and treatment. Oral Surg Oral Med Oral Pathol 1981;52:387-390.
47. Mattson JS, Blankenau R, Keene JJ. Case report. Use of an argon laser to treat drug-induced gingival overgrowth. J Am Dent Assoc 1998;129:78-83.
48. Daley TD, Wysocki GP, Mamandras AH. Orthodontic therapy in the patient treated with cyclosporine. Am J Orthod Dentofacial Orthop 1991;100:537-541.
49. Abitbol TE, Rosenfeld-Abitbol M. Surgical treatment of nifedipine-induced gingival hyperplasia. A case report. NY State Dent J 1996;62:34-37.
50. Barclay S, Thomason JM, Idle JR, Seymour RA. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992;19:311-314.
51. Steele RM, Schuna AA, Schreiber RT. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994;120:663-664.
52. Dahllof G, Reinholt FP, Hjerpe A, Modeer T. A quantitative analysis of connective tissue components in phenytoin-induced gingival overgrowth in children. A stereological study. J Periodontal Res 1984;19:401-407.
53. Dahllof G, Modeer T, Reinholt FP, Wikstrom B, Hjerpe A. Proteoglycans and glycosaminoglycans in phenytoin-induced gingival overgrowth. J Periodontal Res 1986;21: 13-21.
54. van der Wall EE, Tuinzing DB, Hes J. Gingival hyperplasia induced by nifedipine, an arterial vasodilating drug. Oral Surg Oral Med Oral Pathol 1985;60:38-40.
55. Nery EB, Edson RG, Lee KK, Pruthi VK, Watson J. Prevalence of nifedipine-induced gingival hyperplasia. J Periodontol 1995;66:572-578.
56. Dupre J, Stiller CR, Gent M, et al. Clinical trials of cyclosporin in IDDM. Diabetes Care 1988; 11 (Suppl. 1): 37-44.